Latest Headlines

Latest Headlines

J&J to pay $2.2B to wrap up long-standing Risperdal marketing probe

Johnson & Johnson has finally made a deal with the Justice Department. The Big Pharma giant agreed to pay $2.2 billion and plead guilty to a misdemeanor to wrap up a long-standing probe into its marketing of the antipsychotic drug Risperdal. 

J&J wins a bright spot after string of recalls

In recent months, Johnson & Johnson has had to recall three different products. But in one positive turn, the company is being allowed to restart production at a baby powder plant in Mumbai, India, that was closed by regulators in June.

J&J recall streak continues with moldy schizophrenia drug

It hasn't been a great couple of weeks for Johnson & Johnson. After recently recalling some 200,000 bottles of Motrin Infants' Drops, Wednesday the company announced its second recall in as many weeks, this time for a schizophrenia drug.

Antipsychotics hike diabetes risk in kids, study finds

Watchdogs worried about antipsychotic use in children now have more ammo. A new study links the drugs with Type 2 diabetes. Published in the journal JAMA Psychiatry, the study found a threefold increase in diabetes risk for kids who take antipsychotic drugs compared with those taking other psychotropic drugs.

Risperdal plaintiff's lawyer demands sealed J&J docs from FDA

If you don't succeed in court, try the FDA. That's the approach of a Philadelphia lawyer who wants to make some Risperdal data public, but is barred from doing so by a federal judge's order.

State AGs ask Arkansas high court to back J&J's $1.2B Risperdal fine

The Arkansas Supreme Court is the epicenter of the latest episode in Johnson & Johnson's Risperdal saga. J&J is appealing the $1.2 billion fine in a Medicaid fraud case, in which a jury found the company had downplayed Risperdal's risks and marketed it for off-label uses.

WSJ: J&J federal Risperdal deal hung up on language over breasts

Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.

J&J fights $327M Risperdal verdict, saying no one was harmed

South Carolina Circuit Judge Roger Couch took a particularly creative approach when he levied a $327 million penalty against Johnson & Johnson in the state's Risperdal case.

Pfizer CEO Ian Read ordered to testify in Chantix case

Another Big Pharma CEO faces the prospect of appearing before a jury to testify in defense of a drug that has been called dangerous.

J&J settles a boatload of Levaquin cases

Johnson & Johnson appears to be in settlement mode. It has knocked off some more pending litigation, having settled about 25% of the 3,400 lawsuits it faced tied to the dangers of taking antibiotic Levaquin. The settlements come after it recently negotiated settlements related to its aggressive marketing of antipsychotic drug Risperdal.